{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:42:11Z","timestamp":1792014131929,"version":"4.4.0"},"reference-count":110,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Cabozantinib was recently approved for the treatment of advanced renal cell carcinoma (RCC) after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. Cabozantinib is a multikinase inhibitor targeting VEGF receptor (VEGFR) 2, mesenchymal-epithelial transition receptor, and \u201canexelekto\u201d receptor tyrosine kinase. A 60-mg daily dose led to improved overall survival and progression-free survival (PFS) versus everolimus in advanced RCC patients as a second- or later-line treatment in the METEOR trial. Improved PFS with cabozantinib versus sunitinib has also been demonstrated in the first-line setting in CABOSUN. However, cabozantinib, like other VEGFR inhibitors, is associated with toxicity that may affect the patient's quality of life. The most frequent adverse events (AEs) are diarrhea, fatigue, hypertension, hand-foot syndrome, weight loss, nausea, and stomatitis. This article summarizes the safety profile of cabozantinib in RCC patients and offers guidance for the management of these AEs. We discuss the underlying mechanisms of these AEs and, based on our experiences with cabozantinib and other multikinase inhibitors, we present approaches to manage toxicity. Prophylactic and therapeutic solutions are available to help with the management of toxicity associated with cabozantinib, and adequate interventions can ensure optimum adherence and maximize patient outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Cabozantinib leads to improved survival outcomes in renal cell carcinoma patients compared with everolimus. However, management of the adverse event profile is crucial to achieve optimum adherence and outcomes with the use of cabozantinib. This review aims to provide appropriate guidance that will minimize the impact of adverse events and help to maximize the utility of this agent in patients with advanced renal cell carcinoma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0335","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T18:23:03Z","timestamp":1510856583000},"page":"306-315","source":"Crossref","is-referenced-by-count":79,"title":["Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma"],"prefix":"10.1093","volume":"23","author":[{"given":"Manuela","family":"Schmidinger","sequence":"first","affiliation":[{"name":"Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacogenetic Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"2021122510333934600_onco12321-bib-0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/332268a0","article-title":"Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma","volume":"332","author":"Seizinger","year":"1988","journal-title":"Nature"},{"key":"2021122510333934600_onco12321-bib-0002","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/01.ju.0000074870.54671.98","article-title":"Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas","volume":"170","author":"Na","year":"2003","journal-title":"J Urol"},{"key":"2021122510333934600_onco12321-bib-0003","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma","volume":"23","author":"Rini","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122510333934600_onco12321-bib-0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"2021122510333934600_onco12321-bib-0005","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2021122510333934600_onco12321-bib-0006","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1574362409666140206223014","article-title":"Mechanisms of acquired resistance to tyrosine kinase inhibitors in clear - Cell Renal Cell Carcinoma (ccRCC)","volume":"8","author":"Bielecka","year":"2014","journal-title":"Curr Signal Transduct Ther"},{"issue":"suppl 1","key":"2021122510333934600_onco12321-bib-0007","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/1758834011422557","article-title":"c-MET as a potential therapeutic target and biomarker in cancer","volume":"3","author":"Sierra","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"2021122510333934600_onco12321-bib-0008","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-10-2527","article-title":"VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer","volume":"71","author":"You","year":"2011","journal-title":"Cancer Res"},{"key":"2021122510333934600_onco12321-bib-0009","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.3390\/cancers6042387","article-title":"Met in urological cancers","volume":"6","author":"Miyata","year":"2014","journal-title":"Cancers (Basel)"},{"key":"2021122510333934600_onco12321-bib-0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"2021122510333934600_onco12321-bib-0011","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0002-9440(10)64058-8","article-title":"Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo","volume":"158","author":"Xin","year":"2001","journal-title":"Am J Pathol"},{"key":"2021122510333934600_onco12321-bib-0012","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/01.CIR.97.4.381","article-title":"Potentiated angiogenic effect of scatter factor\/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis","volume":"97","author":"Belle","year":"1998","journal-title":"Circulation"},{"key":"2021122510333934600_onco12321-bib-0013","doi-asserted-by":"crossref","first-page":"13373","DOI":"10.1073\/pnas.1404848111","article-title":"Direct regulation of GAS6\/AXL signaling by HIF promotes renal metastasis through SRC and MET","volume":"111","author":"Rankin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122510333934600_onco12321-bib-0014","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"2021122510333934600_onco12321-bib-0015","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"2021122510333934600_onco12321-bib-0016","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.12659\/MSM.893590","article-title":"Cabozantinib, a novel c-Met inhibitor, inhibits colorectal cancer development in a xenograft model","volume":"21","author":"Sun","year":"2015","journal-title":"Med Sci Monit"},{"key":"2021122510333934600_onco12321-bib-0017","doi-asserted-by":"crossref","first-page":"e58262","DOI":"10.1371\/journal.pone.0058262","article-title":"Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2","volume":"8","author":"Navis","year":"2013","journal-title":"PLoS One"},{"key":"2021122510333934600_onco12321-bib-0018","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1096\/fasebj.12.13.1267","article-title":"Interactions between scatter factors and their receptors: hints for therapeutic applications","volume":"12","author":"Trusolino","year":"1998","journal-title":"FASEB J"},{"key":"2021122510333934600_onco12321-bib-0019","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.beem.2008.09.012","article-title":"Receptor tyrosine kinase inhibitors in thyroid cancer","volume":"22","author":"Castellone","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2021122510333934600_onco12321-bib-0020","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2174\/187152008784533035","article-title":"Antiangiogenic drugs and tyrosine kinases","volume":"8","author":"Timar","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"2021122510333934600_onco12321-bib-0021","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122510333934600_onco12321-bib-0022","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510333934600_onco12321-bib-0023","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122510333934600_onco12321-bib-0024","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122510333934600_onco12321-bib-0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ced.12694","article-title":"Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis","volume":"41","author":"Belum","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2021122510333934600_onco12321-bib-0026","first-page":"e61","article-title":"The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life","volume":"11","author":"Nardone","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"2021122510333934600_onco12321-bib-0027"},{"key":"2021122510333934600_onco12321-bib-0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of cabozantinib","volume":"56","author":"Lacy","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2021122510333934600_onco12321-bib-0029","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/CAD.0000000000000366","article-title":"Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults","volume":"27","author":"Nguyen","year":"2016","journal-title":"Anticancer Drugs"},{"key":"2021122510333934600_onco12321-bib-0030","year":"2017"},{"key":"2021122510333934600_onco12321-bib-0031","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/jcph.714","article-title":"Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib","volume":"56","author":"Nguyen","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2021122510333934600_onco12321-bib-0032","year":"2017"},{"key":"2021122510333934600_onco12321-bib-0033","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/jcph.526","article-title":"Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects","volume":"55","author":"Nguyen","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2021122510333934600_onco12321-bib-0034","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jcph.510","article-title":"Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK","volume":"55","author":"Nguyen","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2021122510333934600_onco12321-bib-0035","year":"2017"},{"key":"2021122510333934600_onco12321-bib-0036","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cncr.29798","article-title":"Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas","volume":"122","author":"Schiff","year":"2016","journal-title":"Cancer"},{"key":"2021122510333934600_onco12321-bib-0037","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdu184","article-title":"A phase I study of cabozantinib (XL184) in patients with renal cell cancer","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122510333934600_onco12321-bib-0038","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122510333934600_onco12321-bib-0039","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122510333934600_onco12321-bib-0040","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial","volume":"17","author":"Neal","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122510333934600_onco12321-bib-0041","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122510333934600_onco12321-bib-0042","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","article-title":"Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients","volume":"22","author":"Tolaney","year":"2017","journal-title":"The Oncologist"},{"key":"2021122510333934600_onco12321-bib-0043","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2016-01-694786","article-title":"Phase IB study of cabozantinib in patients with relapsed and\/or refractory multiple myeloma","volume":"127","author":"Lendvai","year":"2016","journal-title":"Blood"},{"key":"2021122510333934600_onco12321-bib-0044","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10637-016-0376-1","article-title":"A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer","volume":"34","author":"Zhen","year":"2016","journal-title":"Invest New Drugs"},{"key":"2021122510333934600_onco12321-bib-0045","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/annonc\/mdw651","article-title":"Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study","volume":"28","author":"Kelley","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122510333934600_onco12321-bib-0046","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122510333934600_onco12321-bib-0047","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1679\/aohc.61.17","article-title":"Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat","volume":"61","author":"Fan","year":"1998","journal-title":"Arch Histol Cytol"},{"key":"2021122510333934600_onco12321-bib-0048","doi-asserted-by":"crossref","first-page":"G1088","DOI":"10.1152\/ajpgi.00250.2001","article-title":"Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells","volume":"282","author":"Wang","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2021122510333934600_onco12321-bib-0049","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.physiol.68.040504.094718","article-title":"Interstitial cells of cajal as pacemakers in the gastrointestinal tract","volume":"68","author":"Sanders","year":"2006","journal-title":"Annu Rev Physiol"},{"key":"2021122510333934600_onco12321-bib-0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ctrv.2010.01.003","article-title":"Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma","volume":"36","author":"Schmidinger","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"2021122510333934600_onco12321-bib-0051","first-page":"387","article-title":"Double-blind, randomized evaluation of clinical efficacy and tolerability of an apple pectin-chamomile extract in children with unspecific diarrhea","volume":"56","author":"Becker","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"2021122510333934600_onco12321-bib-0052","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00005176-198905000-00010","article-title":"Tannin-rich carob pod for the treatment of acute-onset diarrhea","volume":"8","author":"Loeb","year":"1989","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2021122510333934600_onco12321-bib-0053","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/thy.2015.0166","article-title":"Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: a pilot study","volume":"25","author":"Dadu","year":"2015","journal-title":"Thyroid"},{"key":"2021122510333934600_onco12321-bib-0054","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6603990","article-title":"Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study","volume":"97","author":"Osterlund","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122510333934600_onco12321-bib-0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2036.2012.05127.x","article-title":"The effects of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by MRI in a mannitol model of secretory diarrhoea","volume":"36","author":"Placidi","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122510333934600_onco12321-bib-0056","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70006-3","article-title":"Guidance on the management of diarrhoea during cancer chemotherapy","volume":"15","author":"Andreyev","year":"2014","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2021122510333934600_onco12321-bib-0057","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000285776","article-title":"Safety profile and clinical recommendations for the use of lapatinib","volume":"5","author":"Chatsiproios","year":"2010","journal-title":"Breast Care (Basel)"},{"key":"2021122510333934600_onco12321-bib-0058","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl"},{"key":"2021122510333934600_onco12321-bib-0059","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2021122510333934600_onco12321-bib-0060","article-title":"Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis","author":"Li","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"2021122510333934600_onco12321-bib-0061","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1080\/10428190801895352","article-title":"Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens","volume":"49","author":"Pratz","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122510333934600_onco12321-bib-0062","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1002\/cncr.25908","article-title":"FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?","volume":"117","author":"Pemmaraju","year":"2011","journal-title":"Cancer"},{"key":"2021122510333934600_onco12321-bib-0063","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jpainsymman.2009.12.006","article-title":"Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers","volume":"40","author":"Miaskowski","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"2021122510333934600_onco12321-bib-0064","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1099800409333871","article-title":"Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue","volume":"11","author":"Aouizerat","year":"2009","journal-title":"Biol Res Nurs"},{"key":"2021122510333934600_onco12321-bib-0065","first-page":"229","article-title":"Distinguishing fatigue and depression in patients with cancer","volume":"8","author":"Jacobsen","year":"2003","journal-title":"Semin Clin Neuropsychiatry"},{"key":"2021122510333934600_onco12321-bib-0066","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1037\/0278-6133.26.4.464","article-title":"Utility of a cognitive\u2013behavioral model to predict fatigue following breast cancer treatment","volume":"26","author":"Donovan","year":"2007","journal-title":"Health Psychol"},{"key":"2021122510333934600_onco12321-bib-0067","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/0-387-26283-0_5","article-title":"The role of immune cells in the tumor microenvironment","volume":"130","author":"Whiteside","year":"2006","journal-title":"Cancer Treat Res"},{"key":"2021122510333934600_onco12321-bib-0068","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/brbi.2000.0613","article-title":"Cytokine-induced sickness behavior: where do we stand?","volume":"15","author":"Dantzer","year":"2001","journal-title":"Brain Behav Immun"},{"key":"2021122510333934600_onco12321-bib-0069","first-page":"CD006145","article-title":"Exercise for the management of cancer-related fatigue in adults","volume":"11","author":"Cramp","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122510333934600_onco12321-bib-0070","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/cncr.28089","article-title":"Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients","volume":"119","author":"Weickhardt","year":"2013","journal-title":"Cancer"},{"key":"2021122510333934600_onco12321-bib-0071","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"2021122510333934600_onco12321-bib-0072","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bbi.2010.09.010","article-title":"Fatigue and gene expression in human leukocytes: Increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue","volume":"25","author":"Bower","year":"2011","journal-title":"Brain Behav Immun"},{"key":"2021122510333934600_onco12321-bib-0073","first-page":"CD006704","article-title":"Drug therapy for the management of cancer-related fatigue","volume":"7","author":"Minton","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122510333934600_onco12321-bib-0074","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/17512433.2016.1190269","article-title":"Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2021122510333934600_onco12321-bib-0075","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2215\/CJN.08111109","article-title":"Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor","volume":"5","author":"Robinson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122510333934600_onco12321-bib-0076","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"2021122510333934600_onco12321-bib-0077","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"2021122510333934600_onco12321-bib-0078","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.ATV.17.11.2793","article-title":"Vascular endothelial growth factor\/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium","volume":"17","author":"Horowitz","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021122510333934600_onco12321-bib-0079","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(97)01481-6","article-title":"Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42\/p44 mitogen-activated protein kinase","volume":"420","author":"Wheeler-Jones","year":"1997","journal-title":"FEBS Lett"},{"key":"2021122510333934600_onco12321-bib-0080","first-page":"123","article-title":"The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model","volume":"31","author":"Wasa","year":"2011","journal-title":"Anticancer Res"},{"key":"2021122510333934600_onco12321-bib-0081","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MPA.0b013e3181c314cd","article-title":"Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells","volume":"39","author":"Gong","year":"2010","journal-title":"Pancreas"},{"key":"2021122510333934600_onco12321-bib-0082","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/187152006778226521","article-title":"Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy","volume":"6","author":"Molteni","year":"2006","journal-title":"Anticancer Agents Med Chem"},{"key":"2021122510333934600_onco12321-bib-0083","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1290\/1071-2690(2002)038<0298:BBIAIC>2.0.CO;2","article-title":"Beta blockade induces apoptosis in cultured capillary endothelial cells","volume":"38","author":"Sommers Smith","year":"2002","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"2021122510333934600_onco12321-bib-0084","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"The Oncologist"},{"key":"2021122510333934600_onco12321-bib-0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"The Oncologist"},{"key":"2021122510333934600_onco12321-bib-0086","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122510333934600_onco12321-bib-0087","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"2021122510333934600_onco12321-bib-0088","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jacc.2005.08.045","article-title":"Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse","volume":"46","author":"Kido","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2021122510333934600_onco12321-bib-0089","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1177\/42.11.7523489","article-title":"Expression of c-kit and kit ligand proteins in normal human tissues","volume":"42","author":"Lammie","year":"1994","journal-title":"J Histochem Cytochem"},{"key":"2021122510333934600_onco12321-bib-0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suponc.2010.12.007","article-title":"Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: Viewpoints from the medical oncologist, dermatologist, and oncology nurse","volume":"9","author":"Manchen","year":"2011","journal-title":"J Support Oncol"},{"key":"2021122510333934600_onco12321-bib-0091","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/acem.12836","article-title":"Intravenous ondansetron and the QT interval in adult emergency department patients: An observational study","volume":"23","author":"Moffett","year":"2016","journal-title":"Acad Emerg Med"},{"key":"2021122510333934600_onco12321-bib-0092","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187231210790980408","article-title":"An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6","volume":"4","author":"Lewis","year":"2010","journal-title":"Drug Metab Lett"},{"key":"2021122510333934600_onco12321-bib-0093","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021122510333934600_onco12321-bib-0094","first-page":"340","article-title":"Molecular pathways leading to cancer cachexia","volume":"20","author":"Tisdale","year":"2005","journal-title":"Physiology (Bethesda)"},{"key":"2021122510333934600_onco12321-bib-0095","first-page":"2359","article-title":"Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients","volume":"58","author":"Hirai","year":"1998","journal-title":"Cancer Res"},{"key":"2021122510333934600_onco12321-bib-0096","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF01262570","article-title":"Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients","volume":"5","author":"Maltoni","year":"1997","journal-title":"Support Care Cancer"},{"key":"2021122510333934600_onco12321-bib-0097","first-page":"G450","article-title":"Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines","volume":"254","author":"Moldawer","year":"1988","journal-title":"Am J Physiol"},{"key":"2021122510333934600_onco12321-bib-0098","first-page":"493","article-title":"Usefulness of oral medroxyprogesterone acetate in the management of cancer-related cachexia-anorexia syndrome","volume":"3","author":"Testa","year":"1996","journal-title":"Oncol Rep"},{"key":"2021122510333934600_onco12321-bib-0099","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.22484","article-title":"Updated clinical practice guidelines for the prevention and treatment of mucositis","volume":"109","author":"Keefe","year":"2007","journal-title":"Cancer"},{"key":"2021122510333934600_onco12321-bib-0100","first-page":"CD000978","article-title":"Interventions for preventing oral mucositis for patients with cancer receiving treatment","volume":"13","author":"Worthington","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 1","key":"2021122510333934600_onco12321-bib-0101","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2001","article-title":"NCCN Task Force Report. Prevention and management of mucositis in cancer care","volume":"6","author":"Bensinger","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122510333934600_onco12321-bib-0102","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"2021122510333934600_onco12321-bib-0103","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr Clin Pharmacol"},{"issue":"suppl 3","key":"2021122510333934600_onco12321-bib-0104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"key":"2021122510333934600_onco12321-bib-0105","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4158\/EP12280.GL","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association","volume":"18","author":"Garber","year":"2012","journal-title":"Endocr Pract"},{"key":"2021122510333934600_onco12321-bib-0106","first-page":"3040","article-title":"Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism","volume":"41","author":"Mishkin","year":"1981","journal-title":"Cancer Res"},{"key":"2021122510333934600_onco12321-bib-0107","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/01.fjc.0000175438.94906.a0","article-title":"The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin","volume":"46","author":"Mousa","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"2021122510333934600_onco12321-bib-0108","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1210\/jc.2011-3399","article-title":"Combination treatment with T4 and T3: Toward personalized replacement therapy in hypothyroidism?","volume":"97","author":"Biondi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122510333934600_onco12321-bib-0109","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V79.3.634.634","article-title":"Role of c-kit ligand in the expansion of human hematopoietic progenitor cells","volume":"79","author":"Brandt","year":"1992","journal-title":"Blood"},{"key":"2021122510333934600_onco12321-bib-0110","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3109\/07357901003631080","article-title":"Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice","volume":"28","author":"Schmidinger","year":"2010","journal-title":"Cancer Invest"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0335","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/3\/306\/41915168\/oncolo_23_3_306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/3\/306\/41915168\/oncolo_23_3_306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:34:49Z","timestamp":1640428489000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/3\/306\/6439316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":110,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,11,16]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0335","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3,1]]},"published":{"date-parts":[[2017,11,16]]}}}